Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide

We use essential cookies to run the site. Analytics cookies are optional and help us improve World Wide. Learn more.

Antisense oligonucleotide mediated exon skipping therapy development for Duchenne muscular dystrophy takes more than an oligonucleotide - World Wide